Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer
Menée à partir de données portant sur 14 patients atteints d'un cancer du poumon non à petites cellules et présentant une altération au niveau des gènes EGFR ou MET (âge médian : 63 ans ; durée médiane de suivi : 8 mois), cette étude analyse la faisabilité et la sécurité d'une radiothérapie concomitante chez les patients recevant de l'amivantamab
Introduction: Amivantamab is increasingly used in EGFR-altered advanced non-small cell lung cancer (NSCLC), but data on the safety and efficacy of concurrent radiation therapy (RT) remain scarce. This study assessed the safety and efficacy of this approach.
Methods: Patients with advanced EGFR- or MET-altered NSCLC who received RT within 3 weeks after amivantamab were retrospectively analyzed. RT-related adverse events (AEs), best clinical and radiological responses, local control (LC), post-RT progression-free survival (PFS), overall survival (OS), time to treatment discontinuation (TTD), and time to new systemic therapy (TTNT) were assessed.
Results: Twenty-one irradiation courses were delivered concurrently with amivantamab in 14 patients. Median age was 63 years; 71% were never-smokers; 86% had received prior systemic therapy. Mutations included EGFR ex19del (64%), L858R (14%), ex20ins (14%), and MET exon 14 skipping (7%). RT indications were oligoprogression (29%) and palliation (71%), targeting the brain (19%), thorax (19%), lumbosacral spine (14%), adrenals (10%), and extremities (10%). Median follow-up was 8.0 months for AEs and 9.5 months for oncologic outcomes. Symptom relief was achieved in 87% of irradiations, and LC was maintained in 80% of cases. RT-related AEs included 13 grade 1 acute, six grade 2 acute, and three grade 1 late events; no grade ≥3 AEs were reported. The 6- and 12-month OS rates were 77% and 50%, respectively. Among 11 patients continuing amivantamab after RT, median PFS, TTD, and TTNT were 4.5, 4.8, and 5.5 months, respectively. Symptom relief was achieved in 87% of palliative irradiations, and LC was maintained in 80% of oligoprogressive lesions.
Conclusions: Concurrent palliative RT and amivantamab appears feasible and well tolerated. Further validation is warranted.
European Journal of Cancer , résumé, 2026